Brokerages Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Target Price at $12.00

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has received an average rating of “Hold” from the eight brokerages that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating on the company. The average 12-month price target among brokers that have covered the stock in the last year is $12.00.

Several brokerages recently commented on JSPR. TD Cowen lowered shares of Jasper Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 15th. Wall Street Zen upgraded shares of Jasper Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Friday, July 17th. Finally, Royal Bank Of Canada set a $3.00 price target on shares of Jasper Therapeutics and gave the stock a “sector perform” rating in a report on Friday, May 15th.

Jasper Therapeutics Price Performance

Shares of NASDAQ:JSPR opened at $0.61 on Thursday. The business’s 50-day moving average is $0.58 and its 200 day moving average is $0.95. Jasper Therapeutics has a 1 year low of $0.32 and a 1 year high of $3.14. The firm has a market capitalization of $16.98 million, a P/E ratio of -0.19 and a beta of 3.02.

Jasper Therapeutics (NASDAQ:JSPR) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.08. On average, analysts expect that Jasper Therapeutics will post -1.67 EPS for the current year.

Hedge Funds Weigh In On Jasper Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in JSPR. Velan Capital Investment Management LP lifted its position in Jasper Therapeutics by 86.1% during the 3rd quarter. Velan Capital Investment Management LP now owns 2,668,395 shares of the company’s stock worth $6,206,000 after acquiring an additional 1,234,567 shares during the period. Goldman Sachs Group Inc. boosted its holdings in Jasper Therapeutics by 6,394.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,746,492 shares of the company’s stock worth $3,196,000 after buying an additional 1,719,602 shares in the last quarter. Acorn Capital Advisors LLC acquired a new stake in Jasper Therapeutics during the third quarter valued at $3,291,000. Millennium Management LLC increased its holdings in Jasper Therapeutics by 194.2% in the fourth quarter. Millennium Management LLC now owns 1,073,783 shares of the company’s stock valued at $1,965,000 after buying an additional 708,844 shares in the last quarter. Finally, Woodline Partners LP purchased a new position in shares of Jasper Therapeutics in the 3rd quarter valued at about $2,475,000. Hedge funds and other institutional investors own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.